Abstract. Lindmarker P, Schulman S, the DURAC Trial Study Group (Karolinska Hospital, Karolinska Institute, Stockholm, Sweden) The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. J Intern Med 2000; 247: 601±606.
Objectives. To investigate the risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg.
Design. An open prospective long term follow-up multicentre trial. Patients were followed by frequent outpatient visits at each centre during the first 12 months after inclusion and thereafter annually. Setting. Sixteen hospitals in central Sweden. Subjects. A total of 790 consecutive patients with objectively verified first episode of acute deep vein thrombosis and without diagnosed malignant disease were recruited from a randomized study comparing 6 weeks with 6 months of oral antivitamin K therapy as secondary thromboprophylaxis. Main outcome measures. Deep vein thrombosis in the contralateral leg was confirmed by venography or ultrasound. With regard to the ipsilateral leg, venography was required. Results. A recurrent episode of venous thromboembolism was documented in 192 patients after a mean (6SD) period of 31(629) months. In 26 additional patients with ipsilateral symptoms the diagnostic critera were not fulfilled. One hundred and eleven patients have deceased and 69 patients withdrew from the study. The 392 patients without recurrent episodes were followed for a median of 96 months with 90% for at least 48 months. An objectively verified recurrent contralateral and ipsilateral deep vein thrombosis occurred in 95 and 54 cases, respectively, and in 41 patients pulmonary embolism was documented. In two patients thromboses with unusual locations were registered. The risk of contralateral versus ipsilateral recurrence was significantly increased with a risk ratio of 1.6 (95% confidence interval 1.4±1.9) in a time to event model. In a multivariate analysis none
Introduction
Epidemiological data suggest that deep vein thrombosis is slightly more frequent in females and in the left leg, which is pronounced in the reproductive age [1±5]. The age matched risk of a recurrent episode of venous thromboembolism is increased approximately 40±50 times compared with the risk for the first event in the general population, making previous episodes of this disease a very strong risk factor for recurrences [6±8] . Several trials have focused on the assessment of risk factors for recurrent venous thromboembolism, such as congenital deficiencies of the coagulation inhibitors and the polymorphisms G1691G/A and G20210G/A in the factor V and prothrombin gene, respectively [9±Virchow more than a century ago and thereafter by numerous authors, it has been assumed that local predisposing factors, such as an impaired blood flow and a defective vein vessel wall function, play a major role in the pathophysiology of venous thrombosis [15] . A previous episode of deep vein thrombosis may cause damaged endothelium and valves in the affected vein resulting in a valvular incompetence in that leg [16] . Recurrent thrombosis in the ipsilateral leg is highly associated with the post trombotic syndrome [17] . The long term risk for ipsilateral versus contralateral recurrent deep vein thrombosis has not been well documented [18] . This was the primary objective in the present prospective study, in addition to analysing potential variables associated with these risks.
Methods

Study design
During the period April 12 1988 to April 18 1991 a total of 902 patients with a first episode of venous thromboembolism were included in this open multicentre trial at 16 hospitals in Sweden (the DURAC 1-trial). Consecutive patients with objectively verified acute deep vein thrombosis and/or pulmonary embolism and without diagnosed malignant disease were randomized to 6 weeks or 6 months of oral antivitamin K therapy as secondary thromboprophylaxis after the acute event. The criteria for inclusion and exclusion, the diagnostic procedures and main results in the DURAC-1 trial were reported in 1995 [8] .
Cardiolipin antibodies in serum and plasma levels of plasminogen activator inhibitor-1 were tested 6 months after inclusion to avoid the influence of acute phase reactions [19] .
The patients were asked to report immediately if symptoms suggestive of recurrent venous thromboembolism developed. They were followed with outpatient visits at each centre 1.5, 3, 6, 9, 12 and 24 months after inclusion. Subsequent controls were performed annually, and are still going on, using a standardized questionnaire focused on symptomatic and objectively verified recurrent venous thromboembolism and diagnosed malignant disease. All diagnostic procedures at inclusion were performed according to defined criteria and evaluated by a`blinded' radiologist. The definition of recurrent episodes was according to predefined criteria as follows: (i) deep vein thrombosis in the contralateral leg was confirmed by venography; (ii) ultrasound of the popliteal vein or more proximal veins was also accepted; (iii) with regard to the ipsilateral leg, venography was required and had to show a thrombus in more than one view and in a deep vein other than the index event or, a proximal extension of at least 5 cm or, if the upper limit of the first thrombus was not determined, the presence of constant filling defect(s) surrounded by contrast medium. Episodes of deep vein thrombosis not fulfilling the defined criteria after the venogram evaluation or a diagnosis of thrombosis in the ipsilateral leg by ultrasound were classified as nondiagnostic; cases where the responsible physician judged that oral antivitamin K therapy was indicated were also judged nondiagnostic. Recurrent pulmonary embolism was verified by pulmonary angiography or lung scanning, showing new defects in originally perfused areas or at the initial location, provided that another lung scan had shown normalization during the intermediate period.
Patients
At inclusion in the DURAC-1 trial 107 out of 902 (11.9%) patients had pulmonary embolism without symptoms of deep vein thrombosis and were not included in the present study. No protein S or antithrombin deficiency was diagnosed by the initial biochemical screening. Five patients with protein C deficiency were identified and excluded from the study. A total of 790 patients remained in the present follow-up study. The study protocol was approved by the regional ethics committee at the Karolinska Institute.
Laboratory methods
The plasma levels of antithrombin, protein C and plasminogen activator inhibitor-1 were analysed by activity methods. The protein S (total and free) levels in plasma were analysed using an immunochemical assay. All methods were commercially available.
Serum was analysed for the presence of immunoglobulin G cardiolipin antibodies by enzyme linked immunosorbent assay using rabbit antihuman IgG conjugant previously described and grouped [20] .
Statistical methods
Descriptive statistics were used for all variables. In the univariate analyses of continuous variables regarding the side of recurrent deep vein thrombosis the Wilcoxon Rank Sum test was used as a nonparametric method. Variables with a normal distribution were analysed with the Student's t-test. For category data Fisher's exact test and x 2 -test were used when applicable. For multivariate analysis a logistic regression model was applied. The proportional hazards test was used in the time-to-event analysis. A P-value of ,0.05 was considered statistically significant. The software JMP 3.1 from SAS, Cary, USA was used.
Results
The characteristics of the 790 patients enrolled in the DURAC±1 trial with a first episode of objectively documented deep vein thrombosis are shown in Table 1 . Due to death or severe intercurrent disease before the 6-month follow-up we were unable to obtain blood samples for the analyses of cardiolipin antibodies and plasminogen activator inhibitor-1 in 9.7% and 12.4% of the patients, respectively.
A recurrent episode of venous thromboembolism was observed in 218 patients (27.6%) after a median follow-up period of 28 months (25th and 75th percentile: 11; 56). In 149 out of the 218 patients, with recurrent venous thromboembolism, a deep vein thrombosis in the leg with or without concomitant symptomatic pulmonary embolism was documented. The diagnostic criteria for the ipsilateral and contralateral leg were fulfilled in 54 (67.5%) and 95 (100%) patients, respectively. In the remaining 26 (32.5%) patients with an ipsilateral location of symptoms the events did not fulfil the diagnostic criteria for a recurrent ipsilateral thrombosis and were classified as nondiagnostic and excluded from further analyses. In 41 out of the 218 patients without symptoms of deep vein thrombosis an episode of symptomatic pulmonary embolism was diagnosed using objective methods. In two patients, thromboses with unusual locations were registered: upper extremity (n = 1) and mesenteric veins (n = 1).
One hundred and eleven patients had deceased after a median follow-up of 45 months (25th and 75th percentile: 22; 69) without diagnosed recurrent venous thromboembolism. Another 69 patients were withdrawn for various reasons (patients wish, geographical inaccessibility, severe disease) after a median follow-up period of 24 months (25th and 75th percentile: 6; 48). In 392 patients no symptomatic recurrent venous thromboembolism has been registered and the follow-up will continue until 10 years after inclusion. Ninety percent and 75% of the patients were followed for at least 48 and 72 months, respectively. In the comparison of ipsilateral versus contralateral location of the recurrent thrombosis the patients characteristics at inclusion and the results of laboratory analyses were similar in the two groups in a univariate analysis, which is shown in Table 2 .
The cumulative proportion of recurrent venous thromboembolism for the patient groups: pulmonary embolism; recurrent ipsilateral and contralateral deep vein thrombosis, are plotted in Fig. 1 . The risk ratio of a recurrent thrombosis in the contralateral versus ipsilateral leg was 1.6 (95% confidence interval 1.4±1.9) in a time-to-event analyses (proportional hazards model). None of the investigated variables, such as age, gender, heredity, idiopathic cause, treatment allocation, the thrombus extension and the presence of cardiolipin antibodies or an impaired fibrinolysis 6 months after inclusion were significantly associated with the risk of ipsilateral (versus contralateral) recurrent thrombosis in a multiple logistic regression model.
The median follow-up periods until a recurrent deep vein thrombosis occurred were 13 and 28 months in the ipsilateral and contralateral leg, respectively (P , 0.005). The patients were divided into two groups: recurrent event within 6 months, and thereafter. The proportion of recurrent thrombosis in the ipsilateral leg within 6 months and thereafter was 59% and 31%, respectively. Out of 27 patients, 25 (93%) with a recurrent episode of venous thrombosis within 6 months were randomized to 6 weeks of antivitamin K therapy of which 16 and nine patients had an ipsilateral and contralateral location, respectively (P = 0.16).
Discussion
Little has been known about the long term clinical course of deep vein thrombosis in contrast to the number of studies focused on short term follow-up.
In the present study we found that the cumulative long term risk of documented recurrent venous thromboembolism was 24.2% after a mean (6SD) follow-up period of 61 6 36 months, which represents a substantial morbidity. The risk ratio of a recurrent thrombosis in the contralateral versus ipsilateral leg was 1.6 regardless of all investigated variables, such as age, gender, heredity, idiopathic cause, the thrombus extension and the presence of cardiolipin antibodies or an impaired fibrinolysis 6 months after inclusion. Our data suggest that the damaged vessel wall and valvular incompetence in a leg previously affected by symptomatic deep vein thrombosis do not have an impact on the long term risk of recurrent thrombosis. These patients seem to be prone to the development of venous thrombosis in both legs and suffer a continuous risk of recurrent events due to a persistant congenital or acquired coagulopathy and/or an impaired endothelial function in the veins or for other unknown reasons.
Our study has a number of limitations that may influence the results. The diagnosis of a recurrent thrombosis in the same leg may be difficult. The measure to avoid false positive results was a rigorous evaluation and a definition of these events in accordance with other investigators [21] . In 26 patients receiving anticoagulant therapy after presenting with symptoms suggesting ipsilateral recurrent thrombosis the results of the diagnostic investigations did not fulfil our criteria and these patients were excluded from the analyses to avoid false positive results. Moreover, the incidence and localization of recurrent events in deceased patients without autopsy and amongst those who were withdrawn are unknown. However, it is unlikely that the side of recurrent deep vein thrombosis per se in those individuals would be different from patients remaining in the study.
In patients with symptoms or signs of deep vein thrombosis in one leg, ultrasound studies have shown that an asymptomatic deep vein thrombus in the opposite leg can be visualized in 5%. These observations imply that we may have overlooked asymptomatic deep vein thrombosis in the opposite leg at diagnosis or when recurrent events were documented. This small proportion of patients with possible bilateral deep vein thrombosis will not change the results or conclusions as it is likely that the proportion of undiagnosed asymptomatic deep vein thrombosis at the index event or later will be similar.
In conclusion, our study verifies the considerable and continuous risk of recurrent venous thromboembolism in a long term perspective and questions the importance of one of the components in the Virchow's triad ± impaired blood flow ± for the recurrence of venous thrombosis.
